Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
Monopar Therapeutics (Nasdaq: MNPR) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monopar Therapeutics (Nasdaq: MNPR) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. CEO Chandler Robinson will engage in a fireside chat and one-on-one meetings at the event. The presentation is scheduled for December 5, 2024, from 10:30-10:55 am Eastern Time at the Lotte New York Palace in New York. Monopar is a clinical-stage biotechnology company that develops innovative treatments for patients with unmet medical needs.
Details
News Market Reaction – MNPR
The recorded move for MNPR in the trading session of this news was +5.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.
Presentation Details:
Date: December 5, 2024
Time: 10:30-10:55 am Eastern Time
Location: Lotte New York Palace, NY, NY
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.